Differences

This shows you the differences between two versions of the page.

--- algae:intellectual_property [2026-09-13 00:27] – [Nagoya Protocol and ABS Obligations] robert
+++ algae:intellectual_property [2026-09-13 17:30] (current) – Mostly rename EURlex robert
@@ Line 15: / Line 15: @@
   * __Biorefinery processes__ — extraction methods, cultivation processes, cell disruption methods — are patentable subject matter where novel and inventive.
   * __Algae-derived products and compositions__ — purified bioactive compounds, formulated products, encapsulated ingredients — are patentable where novel.
-  * __GMO-derived algal innovations__: genetically modified microorganisms themselves, and sequences used to modify them, are potentially patentable (the EU Biotech Directive, Directive 98/44/EC [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A31998L0044|EUR-Lex]], governs the patentability of biological inventions). However, essentially biological processes for the production of plants or animals (including algae where they are treated as plants) are not patentable.
+  * __GMO-derived algal innovations__: genetically modified microorganisms themselves, and sequences used to modify them, are potentially patentable (the EU Biotech Directive, Directive 98/44/EC [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A31998L0044|EURlex]], governs the patentability of biological inventions). However, essentially biological processes for the production of plants or animals (including algae where they are treated as plants) are not patentable.
 The __Unitary Patent__ ([[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32012R1257|Regulation (EU) No 1257/2012]]) now provides a single patent right covering all participating EU member states after grant by the EPO, significantly reducing the cost of EU-wide patent protection compared to validating European patents in each member state separately.
@@ Line 25: / Line 25: @@
 Plant variety rights (PVR) protect new varieties of plants, conferring exclusive rights over the production and commercialisation of propagating material. In the EU, a unitary Community Plant Variety Right (CPVR) is available through the Community Plant Variety Office (CPVO) under:
-Council Regulation (EC) No 2100/94 of 27 July 1994 on Community plant variety rights, OJ L 227, 1.9.1994, p. 1. [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A01994R2100-20080131|EUR-Lex]]
+Council Regulation (EC) No 2100/94 of 27 July 1994 on Community plant variety rights, OJ L 227, 1.9.1994, p. 1. [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A01994R2100-20080131|EURlex]]
 __Relevance to algae:__ The applicability of plant variety rights to algae is uncertain and untested. The CPVR Regulation covers plant varieties defined by their phenotypic characteristics; the CPVO examinations are designed for conventional terrestrial crops. The legal classification of algae as "plants" (which they are biologically for most macro- and microalgae, though cyanobacteria are bacteria) does not automatically mean that the CPVR system is practically accessible or administratively set up for algae. No CPVR registrations for algae species are known to exist as of 2026.
@@ Line 35: / Line 35: @@
 ==== Trade Secrets ====
-Directive (EU) 2016/943 of the European Parliament and of the Council of 8 June 2016 on the protection of undisclosed know-how and business information (trade secrets), OJ L 157, 15.6.2016, p. 1. [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016L0943|EUR-Lex]]
+Directive (EU) 2016/943 of the European Parliament and of the Council of 8 June 2016 on the protection of undisclosed know-how and business information (trade secrets), OJ L 157, 15.6.2016, p. 1. [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016L0943|EURlex]]
 __Relevance to algae:__ Trade secrets are commercially valuable information kept confidential and subject to reasonable measures to maintain that confidentiality. In the algae industry, trade secrets are frequently more practically protective than patents, particularly for:
@@ Line 50: / Line 50: @@
 ==== Nagoya Protocol and ABS Obligations ====
-The Nagoya Protocol on Access and Benefit-Sharing (ABS), implemented in EU law by Regulation (EU) No 511/2014 [[https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32014R0511|EUR-Lex]], is covered in detail in [[algae:environment_alien_species|Environment and Use of Non-native Species]]. Its relevance to IP is direct: when a novel algal strain sourced from a third country's genetic resources is developed into a commercially valuable IP asset (patented strain, proprietary culture collection), the ABS obligations on benefit-sharing with the country of origin attach to that commercial utilisation. An IP strategy for an algae business built on genetic resources from third countries must integrate ABS compliance — ABS non-compliance can result in IP rights being unenforceable or the commercial exploitation being challenged.
+The Nagoya Protocol on Access and Benefit-Sharing (ABS), implemented in EU law by Regulation (EU) No 511/2014 [[https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32014R0511|EURlex]], is covered in detail in [[algae:environment_alien_species|Environment and Use of Non-native Species]]. Its relevance to IP is direct: when a novel algal strain sourced from a third country's genetic resources is developed into a commercially valuable IP asset (patented strain, proprietary culture collection), the ABS obligations on benefit-sharing with the country of origin attach to that commercial utilisation. An IP strategy for an algae business built on genetic resources from third countries must integrate ABS compliance — ABS non-compliance can result in IP rights being unenforceable or the commercial exploitation being challenged.
 ----